Posted 2/26/16 on Employee Benefit News. The Congressional committee that recently demanded Martin Shkreli’s appearance must have hoped to spotlight a
BRIAN KLEPPER Posted 10/23/15 on The Health Care Blog A new study in JAMA Internal Medicine finds that two-thirds of cancer
…striving for ever-higher earnings, drug companies large and small are relentlessly increasing pricing on old and new drugs because they can. They can because the industry successfully deployed lobbyists who persuaded a receptive Congress to heavily favor their interests, spinning laws away from regulatory controls and toward payment at any price. These circumstances, nurtured by pharma itself, make a 55-fold price increase possible and legal, if outrageous. And that’s the elephant in the room.
Alison Bass First posted 8/10/11 on Alison Bass The retraction of studies in medical and scientific journals has surged in
Alison Bass First posted 8/3/11 on Alison Bass Medicare and social services for vulnerable Americans are not the only programs